Skip to content
Clinical Trials – home

Klinikum Bayreuth GmbH

Verified siteinfo

Germany Hohe Warte 8, Gruener Baum, 95445 Bayreuth, Germany

  • 17 trials recruiting
  • Dementia Alzheimer's type · Breast cancer · Colorectal cancer metastatic
  • Adult patients

About Specializations

Klinikum Bayreuth GmbH in Bayreuth, Germany specialises in clinical trials of conditions such as Dementia Alzheimer's type, Breast cancer, Colorectal cancer metastatic, Relapsing multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases

The Neurology department at Klinikum Bayreuth conducts research on neurodegenerative and inflammatory disorders of the central nervous system, seeking to advance treatment options for patients.

  • Mild Cognitive Impairment due to Alzheimer's Disease
  • Alzheimer's Disease Dementia
  • Relapsing Forms of Multiple Sclerosis
  • Progressive Multiple Sclerosis

With four active studies and eight investigators, the site evaluates new therapies for cognitive decline and multiple sclerosis, aiming to improve safety, tolerability, and disease‑modifying outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Hohe Warte 8, Gruener Baum95445 BayreuthGermany
Recruiting now
17 trials
Conditions studied
39
Partner status
Verified site

More sites in BayreuthGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

39 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Malic acid
  • Sponsor:Universitaet Muenster

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fruquintinib
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Constipation

Recruiting

Safety and tolerability study of sodium hydrogen carbonate and sodium dihydrogen phosphate suppository treatment in adult patients with chronic constipation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium dihydrogen phosphate
  • Sponsor:Athenstaedt GmbH & Co. KG

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Charite Universitaetsmedizin Berlin KöR
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.